Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 11, 2015-06 ,pp. : 1220-1221

John Wiley & Sons Inc

Access to resources Recommend Favorite

Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 768-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

By Li Yuqin  

Wiener klinische Wochenschrift, Vol. 122, Iss. 13-14, 2010-07 ,pp. : 413-422

Springer Publishing Company

Access to resources Recommend Favorite

Letter: possible association of PPI use and spontaneous bacterial peritonitis – authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 6, 2015-09 ,pp. : 779-780

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Clinical Trial for Prevention of Delayed Diarrhea with Cholestyramine/Levofloxacin in the Second-Line Treatment with Irinotecan Biweekly in Patients with Metastatic Colorectal Carcinoma

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 10-16

Karger

Access to resources Recommend Favorite